XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Total
Class A Common Stock
Additional Paid-In Capital
Accumulated other comprehensive loss
Retained Earnings (Accumulated Deficit)
Balance, shares at Jun. 30, 2022   27,046,790      
Balance, amount at Jun. 30, 2022 $ 29,731,238 $ 270,468 $ 232,315,003 $ 935,125 $ (203,789,358)
Employee Stock Purchase Plan, shares   16,287      
Employee Stock Purchase Plan, amount 19,870 $ 163 19,707 0 0
Exercise of Stock Options and RSUs, net, shares   8,852      
Exercise of Stock Options and RSUs, net, amount 0 $ 88 (88) 0 0
Stock-based compensation on stock options and RSUs 284,598 0 284,598 0 0
Foreign currency translation adjustment (917,829) 0 0 (917,829) 0
Net loss (1,380,700) $ 0 0 0 (1,380,700)
Balance, shares at Sep. 30, 2022   27,071,929      
Balance, amount at Sep. 30, 2022 27,737,177 $ 270,719 232,619,220 17,296 (205,170,058)
Balance, shares at Jun. 30, 2023   37,344,739      
Balance, amount at Jun. 30, 2023 35,952,525 $ 373,447 242,808,771 606,536 (207,836,229)
Employee Stock Purchase Plan, shares   14,607      
Employee Stock Purchase Plan, amount 19,719 $ 146 19,573 0 0
Foreign currency translation adjustment (125,208) 0 0 (125,208) 0
Net loss (1,342,376) $ 0 0 0 (1,342,376)
Exercise of Stock Options, RSUs and RSAs net, shares   14,482      
Exercise of Stock Options, RSUs and RSAs net, amount 0 $ 145 (145) 0 0
Issuance of common stock for acquisition of Visimid, shares   81,610      
Issuance of common stock for acquisition of Visimid, amount 150,000 $ 816 149,184 0 0
Stock-based compensation on stock options, RSUs and RSAs 240,075 $ 0 240,075 0 0
Balance, shares at Sep. 30, 2023   37,455,438      
Balance, amount at Sep. 30, 2023 $ 34,894,735 $ 374,554 $ 243,217,458 $ 481,328 $ (209,178,605)